Company intelligence / Profile preview

ActivBiotics

Lexington, Massachusetts, United Statespmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Development stage: Other

Overview

ActivBiotics developed rifalazil, a next-generation rifamycin antibiotic that showed efficacy in Phase 2 trials for chlamydia and was tested in peripheral arterial disease but failed to meet endpoints there. The company also had SOD mimetic compounds in preclinical and discontinued stages. After clinical failure, all assets were sold off through an assignment process.

Therapeutic areas: NeurologyInfectious DiseasesImmunologyRheumatologyCardiovascular
Modalities: Small molecule
Industry: Biotech

Partnerships

Evotec OAI for drug discovery collaboration

Beyond the preview

Go deeper on ActivBiotics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ActivBiotics.

Explore the full profile